Index
RUT
P/E
-
EPS (ttm)
-1.12
Insider Own
14.70%
Shs Outstand
411.94M
Perf Week
7.87%
Market Cap
1.52B
Forward P/E
-
EPS next Y
-0.22
Insider Trans
0.00%
Shs Float
351.42M
Perf Month
-23.55%
Enterprise Value
1.28B
PEG
-
EPS next Q
-0.15
Inst Own
57.16%
Perf Quarter
41.76%
Income
-390.98M
P/S
5.79
EPS this Y
53.26%
Inst Trans
15.05%
Perf Half Y
63.00%
Sales
263.44M
P/B
2.18
EPS next Y
57.07%
ROA
-42.88%
Perf YTD
35.53%
Book/sh
1.70
P/C
5.13
EPS next 5Y
79.45%
ROE
-55.50%
52W High
5.63 -34.28%
Perf Year
20.92%
Cash/sh
0.72
P/FCF
-
EPS past 3/5Y
23.93% 10.23%
ROIC
-52.62%
52W Low
1.64 125.82%
Perf 3Y
-33.69%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
17.09%
Volatility
11.40% 8.82%
Perf 5Y
-87.74%
Dividend TTM
-
EV/Sales
4.85
EPS Y/Y TTM
13.67%
Oper. Margin
-151.18%
ATR (14)
0.34
Perf 10Y
-32.60%
Dividend Ex-Date
-
Quick Ratio
2.83
Sales Y/Y TTM
60.57%
Profit Margin
-148.41%
RSI (14)
51.33
Dividend Gr. 3/5Y
- -
Current Ratio
3.20
EPS Q/Q
31.43%
SMA20
1.47%
Beta
0.82
Payout
-
Debt/Eq
0.07
Sales Q/Q
17.66%
SMA50
6.44%
Rel Volume
2.90
Prev Close
4.01
Employees
975
LT Debt/Eq
0.06
SMA200
40.72%
Avg Volume
15.24M
Price
3.70
IPO
Sep 01, 2009
Option/Short
Yes / Yes
Trades
Volume
44,169,864
Change
-7.73%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-25-26 Upgrade Citizens
Mkt Perform → Mkt Outperform
$5
Jul-15-25 Downgrade Goldman
Neutral → Sell
$1
May-16-25 Downgrade UBS
Buy → Neutral
$2
May-12-25 Downgrade Truist
Buy → Hold
May-09-25 Downgrade Citizens JMP
Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS
Buy
$17
Jul-29-24 Downgrade Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated Goldman
Buy
$12
Sep-18-23 Reiterated Barclays
Overweight
$40 → $18
May-30-23 Upgrade Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated Guggenheim
Neutral
Aug-18-22 Resumed Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed Cowen
Outperform
Jun-10-21 Upgrade JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade Stifel
Buy → Hold
Show Previous Ratings
Mar-31-26 08:49PM
Mar-24-26 10:00AM
Mar-20-26 05:15PM
Mar-07-26 08:10PM
01:28AM
01:06PM
Loading…
Mar-06-26 01:06PM
12:01PM
Mar-05-26 09:00AM
Feb-26-26 02:27PM
09:40AM
08:00AM
Feb-25-26 01:33PM
11:01AM
Feb-24-26 04:32PM
04:01PM
02:14PM
Loading…
02:14PM
12:49PM
09:40AM
09:02AM
07:26AM
(Associated Press Finance)
07:00AM
07:00AM
Feb-23-26 09:58AM
Feb-20-26 05:15PM
Feb-19-26 09:58AM
Feb-17-26 08:41PM
Feb-11-26 06:39PM
04:05PM
Feb-06-26 11:02AM
Feb-05-26 05:15PM
05:15PM
Loading…
Jan-16-26 05:15PM
Jan-15-26 02:33PM
Dec-31-25 11:13AM
Dec-29-25 09:50AM
Dec-19-25 05:15PM
Dec-07-25 09:45AM
Nov-21-25 05:15PM
Nov-11-25 06:45AM
Nov-07-25 01:45PM
08:45AM
Nov-06-25 09:15AM
08:19AM
(Associated Press Finance)
08:00AM
Nov-05-25 05:20PM
Nov-04-25 06:00PM
Nov-03-25 10:00AM
07:00AM
Oct-23-25 04:05PM
Oct-17-25 05:15PM
06:17AM
Oct-15-25 08:45AM
Oct-13-25 05:53AM
Sep-20-25 02:43AM
Sep-19-25 05:00PM
10:05AM
Sep-17-25 08:30AM
Sep-08-25 12:30AM
Aug-29-25 08:30AM
Aug-27-25 04:28PM
Aug-26-25 09:17AM
Aug-25-25 05:15PM
10:30AM
(Associated Press Finance)
08:48AM
Aug-24-25 09:30AM
Aug-22-25 11:45PM
(Insider Monkey)
+5.91%
-5.95%
05:15PM
Aug-19-25 03:16PM
Aug-18-25 04:15PM
Aug-17-25 11:41PM
Aug-14-25 12:22PM
Aug-13-25 10:30AM
(Associated Press Finance)
+9.87%
Aug-12-25 05:31PM
Aug-09-25 04:21AM
Aug-08-25 07:31PM
(Motley Fool)
-20.08%
-6.64%
12:47PM
Aug-07-25 05:10PM
04:20PM
(Associated Press Finance)
04:01PM
06:02AM
Aug-06-25 06:10PM
Aug-05-25 06:05PM
Aug-01-25 06:46AM
Jul-30-25 04:46AM
Jul-29-25 03:29AM
Jul-24-25 04:05PM
10:30AM
(Associated Press Finance)
Jul-23-25 10:30AM
(Associated Press Finance)
+26.84%
Jul-21-25 08:30AM
Jul-18-25 05:15PM
Jul-15-25 07:30AM
Jul-14-25 07:30AM
Jul-10-25 04:01PM
Jul-06-25 06:47AM
Jun-29-25 08:36AM
Jun-27-25 06:57PM
12:00PM
Jun-24-25 01:36PM
09:00AM
Jun-23-25 04:05PM
Jun-20-25 11:56AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel Mar 05 '26 Option Exercise 0.00 62,493 0 556,293 Mar 06 05:02 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 05 '26 Option Exercise 0.00 31,246 0 148,477 Mar 06 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 05 '26 Option Exercise 0.00 39,059 0 257,590 Mar 06 05:00 PM BILINSKY IGOR Chief Operating Officer Mar 05 '26 Option Exercise 0.00 31,246 0 142,394 Mar 06 05:00 PM Vogt Frederick G Interim CEO & General Counsel Mar 02 '26 Option Exercise 0.00 52,087 0 516,609 Mar 04 05:01 PM BILINSKY IGOR Chief Operating Officer Mar 02 '26 Option Exercise 0.00 12,307 0 118,051 Mar 04 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 02 '26 Option Exercise 0.00 5,470 0 221,329 Mar 04 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 02 '26 Option Exercise 0.00 12,697 0 124,353 Mar 04 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 24 '26 Option Exercise 0.00 120,000 0 173,546 Feb 26 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 10 '26 Option Exercise 0.00 39,996 0 69,996 Feb 12 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '25 Option Exercise 0.00 3,906 0 113,640 Dec 03 05:04 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 01 '25 Option Exercise 0.00 8,789 0 114,198 Dec 03 05:04 PM BILINSKY IGOR Chief Operating Officer Dec 02 '25 Option Exercise 0.00 3,516 0 107,530 Dec 03 05:02 PM BILINSKY IGOR Chief Operating Officer Dec 01 '25 Option Exercise 0.00 8,789 0 108,478 Dec 03 05:02 PM Vogt Frederick G Interim CEO & General Counsel Dec 02 '25 Option Exercise 0.00 10,417 0 468,948 Dec 03 05:01 PM Vogt Frederick G Interim CEO & General Counsel Dec 01 '25 Option Exercise 0.00 41,669 0 476,232 Dec 03 05:01 PM Puri Raj K. Chief Regulatory Officer Dec 01 '25 Option Exercise 0.00 5,469 0 218,326 Dec 03 05:00 PM Vogt Frederick G Interim CEO & General Counsel Sep 02 '25 Option Exercise 0.00 52,086 0 456,690 Sep 04 06:35 PM Puri Raj K. Chief Regulatory Officer Sep 02 '25 Option Exercise 0.00 5,470 0 215,324 Sep 04 06:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 02 '25 Option Exercise 0.00 12,697 0 111,857 Sep 04 06:30 PM BILINSKY IGOR Chief Operating Officer Sep 02 '25 Option Exercise 0.00 12,306 0 105,939 Sep 04 06:30 PM Kirby Daniel Gordon Chief Commercial Officer Jun 05 '25 Buy 1.84 30,000 55,200 30,000 Jun 06 04:05 PM Puri Raj K. Chief Regulatory Officer Jun 02 '25 Option Exercise 0.00 5,469 0 212,321 Jun 04 04:51 PM Vogt Frederick G Interim CEO & General Counsel Jun 02 '25 Option Exercise 0.00 52,085 0 426,731 Jun 04 04:50 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 02 '25 Option Exercise 0.00 12,695 0 105,608 Jun 04 04:49 PM BILINSKY IGOR Chief Operating Officer Jun 02 '25 Option Exercise 0.00 12,305 0 99,883 Jun 04 04:47 PM Bellemin Jean-Marc Chief Financial Officer Jun 02 '25 Option Exercise 0.00 8,789 0 64,993 Jun 04 04:46 PM Puri Raj K. Chief Regulatory Officer May 23 '25 Buy 1.74 5,600 9,743 206,852 May 27 04:06 PM Vogt Frederick G Interim CEO & General Counsel May 14 '25 Buy 1.69 25,000 42,250 374,646 May 16 04:05 PM
